CN104784214A - 一种美洲大蠊提取物微孔渗透泵片及其制备方法 - Google Patents
一种美洲大蠊提取物微孔渗透泵片及其制备方法 Download PDFInfo
- Publication number
- CN104784214A CN104784214A CN201410794148.7A CN201410794148A CN104784214A CN 104784214 A CN104784214 A CN 104784214A CN 201410794148 A CN201410794148 A CN 201410794148A CN 104784214 A CN104784214 A CN 104784214A
- Authority
- CN
- China
- Prior art keywords
- periplaneta americana
- osmotic pump
- americana extract
- coating
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000238675 Periplaneta americana Species 0.000 title claims abstract description 58
- 230000003204 osmotic effect Effects 0.000 title claims abstract description 50
- 239000000284 extract Substances 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title abstract description 5
- 239000011248 coating agent Substances 0.000 claims abstract description 43
- 238000000576 coating method Methods 0.000 claims abstract description 43
- 239000000463 material Substances 0.000 claims abstract description 15
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 14
- 239000000314 lubricant Substances 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 239000012528 membrane Substances 0.000 claims abstract description 10
- 239000004014 plasticizer Substances 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 54
- 239000000243 solution Substances 0.000 claims description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims description 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 9
- 238000007873 sieving Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 229920002301 cellulose acetate Polymers 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 239000007779 soft material Substances 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229960004793 sucrose Drugs 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920000875 Dissolving pulp Polymers 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 235000011147 magnesium chloride Nutrition 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 229940093430 polyethylene glycol 1500 Drugs 0.000 claims description 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims description 2
- 229910052939 potassium sulfate Inorganic materials 0.000 claims description 2
- 235000011151 potassium sulphates Nutrition 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000001069 triethyl citrate Substances 0.000 claims description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000013769 triethyl citrate Nutrition 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 229910002012 Aerosil® Inorganic materials 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 16
- 230000002035 prolonged effect Effects 0.000 abstract description 2
- 210000002381 plasma Anatomy 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 8
- 238000000605 extraction Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 102100029677 Trehalase Human genes 0.000 description 1
- 108010087472 Trehalase Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229940093497 ergothioneine Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- -1 protocatechuic acid glucoside Chemical class 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
本发明属于制药领域,具体涉及一种美洲大蠊提取物微孔渗透泵片及其制备方法。其特征在于,先将处方量美洲大蠊提取物、渗透压促进剂、阻滞剂、润滑剂等压片制成片芯,再进行包衣制得,制备所述微孔渗透泵片的主要原辅料质量配比如下:美洲大蠊提取物:53份;渗透压促进剂:50-100份;阻滞剂:50-100份;润滑剂:0.5-2份;半透膜材料:30份;增塑剂:3-15份;致孔剂:3-15份;溶剂:1-100:1。本发明提供了一种美洲大蠊提取物微孔渗透泵制剂,使美洲大蠊提取物可以在12小时内持续恒速释放药物,保持血浆药物浓度的稳定,延长药物作用时间。
Description
技术领域
本发明属于制药领域,具体涉及一种美洲大蠊提取物微孔渗透泵片及其制备方法。
背景技术
美洲大蠊(Periplaneta americana)为蜚镰科大镰属动物,是传统的中药材,以成虫入药。性寒味咸,有毒,有辛辣味、有散瘀、消积、解毒、利水、消肿等功能。现代研究发现,美洲大蠊表皮含有巩膜质、甲壳质、溴、锌、镍、 锰、钾、钙、钛、氯、硫、硅、铝、镁等元素,肌肉水解 13 种氨基酸,身体贮藏维生素B1、B2、烟酸和抗坏血酸等,淋巴含海藻糖、海藻糖酶、糖蛋白、肌醇、原儿茶酸葡萄甙等,全体含麦角硫因、龙虾肌碱、胡芦巴碱、甘氨酸、甜菜碱、肛碱、三甲胺、腺嘌呤等。干燥虫体提取物,含有 WHF( 多元醇类、表皮生长因子 )、粘氨酸、粘糖氨酸及多种氨基酸等活性物质,具有抗炎、消肿、促进细胞增殖和新生肉芽组织增长,加速病损组织修复,加快坏死组织脱落,提高机体免疫功能等作用。
美洲大蠊目前在治疗烧烫伤、口腔溃疡、胃溃疡、痔疮、肛裂、胃炎和消化性胃溃疡、胃溃疡性结肠炎、妇科疾病、尿布疹、过敏性鼻炎、抗肿瘤等方面均有应用。
但是,目前的应用多为传统中药应用方式,部分应用是干燥成虫作为药物组方的一部分,部分是将其提取物与其他药物配伍使用。专利CN201310206244.0将美洲大蠊成分制成胃漂浮片,在胃中停留更久,作用时间更长,可以更好的治疗幽门螺杆菌感染胃炎、消化性溃疡和胃癌。
本发明将美洲大蠊提取物制备成微孔渗透泵片,恒速释药,可使药物在体内保持稳定的血药浓度,避免普通制剂的“峰谷”现象,从而降低不良反应,延长药物作用时间。并且在制备工艺上,微孔控释渗透不需要在包衣膜上进行机械打孔,而是在膜材料中加入致孔剂,致孔剂主要为多元醇及其衍生物或水溶性高分子,水溶性致孔剂在体内遇水溶解形成微孔,药物在渗透压的作用下通过微孔持续释放,从而达到了缓释的作用。
发明内容
本发明的目的是提供了一种美洲大蠊提取物微孔渗透泵制剂,使美洲大蠊提取物可以在12小时内持续恒速释放药物,保持血浆药物浓度的稳定,延长药物作用时间。
本发明的美洲大蠊提取物微孔渗透泵片由片芯和包衣组成,将美洲大蠊提取物、渗透压促进剂、阻滞剂、润滑剂等压片制成片芯,采用适宜的成膜材料、增塑剂和致孔剂对片剂进行包衣制得。渗透泵片芯的重量配比为:
片芯
美洲大蠊提取物:53份;
渗透压促进剂:50-100份;
阻滞剂:50-100份;
润滑剂:0.5-2份;
包衣液
半透膜材料 :30 份;
增塑剂 :3-15份 ;
致孔剂:3-15 份;
溶剂:1-100:1;
其中,所述的美洲大蠊提取物为乙醇提取物,根据专利CN 102885857 B提取得到。美洲大蠊提取物提取步骤包括:
A、粉碎:将干燥的美洲大蠊虫体粉碎,过24目筛,制得美洲大蠊粗粉;
B、浸泡:将步骤A所得美洲大蠊粗粉用浓度90-95%的乙醇浸泡,使乙醇液面高出粗粉液面5-10cm密闭保存制得粗粉混合液;
C、提取:将步骤B所得粗粉混合液在70-85℃的温度下进行4次回流提取,对粗粉混合液进行第一次提取时,加粗粉重量5倍量浓度92%的乙醇,提取时间为5小时;第二次以后每次提取加粗粉重量5倍量浓度92%的乙醇,提取时间为4小时;合并提取液,过滤得乙醇提取液;
D、一级浓缩:将步骤C所得乙醇提取液在真空度-0.05--0.06MPa、 温度50-60℃的条件下减压浓缩,至比重为1.05-1.15时,得乙醇浓缩液;
E、脱脂:将步骤D所得乙醇浓缩液加入乙醇浓缩液重量8倍量的纯化水,边搅拌边升温至85-95℃后,搅拌40分钟,搅拌速度为40转/分,然后保温静置4小时使油水分层 ;
F、二级浓缩:将步骤E所得下层水液放出,经滤纸过滤后,滤液在温度60-80℃、真空度-0.05--0.06MPa 条件下减压浓缩,浓缩至比重为1.25-1.35时,得美洲大蠊提取物。其中,
美洲大蠊含水量约为25%。
所述的渗透压促进剂选自氯化钾、氯化钠、氯化镁、硫酸钾、蔗糖、乳糖、葡萄糖、甘露醇、山梨醇、果糖中的一种、二种或三种。
所述的阻滞剂选自羟丙甲纤维素HPMC K4M、HPMC K15M、HPMC K100M中的一种、二种或三种。
所述的润滑剂选自硬脂酸镁、滑石粉、微粉硅胶中的一种、二种或三种。
所述的半透膜材料选自醋酸纤维素和乙基纤维素中的一种或二种。
所述的增塑剂选自甘油、丙二醇、聚乙二醇、柠檬酸三乙酯、邻苯二甲酸二乙酯、甘油三酯中的一种、二种或三种。
所述的致孔剂选自甘蔗糖、甘露醇、聚乙二醇400、聚乙二醇1500、聚乙二醇2000、聚乙二醇4000、聚乙烯吡咯烷酮中的一种或二种。
所述的溶剂选自丙酮、乙醇、异丙醇中的一种或二种。
所述优选的,微孔渗透泵片每1000片原辅料组成如下:
片芯(1000片)
美洲大蠊提取物: 53g;
氯化钠:80g;
HPMC K4M:80g;
硬脂酸镁:1g;
包衣液(1000mL)
醋酸纤维素:30g;
邻苯二甲酸二乙酯:6mL ;
聚乙二醇400:12mL;
丙酮:乙醇 :950mL:50mL。
本发明的制备方法,其包括以下步骤:
按处方量称取美洲大蠊提取物、渗透压促进剂、阻滞剂,混合均匀过60目筛,加95%乙醇溶液适量制软材,20目筛制粒,50℃干燥2h,过24目筛整粒,加入润滑剂混匀,压片,制得片芯;将半透膜材料、增塑剂、致孔剂溶于溶剂中,即得包衣液;采用薄膜包衣,包衣温度 30℃,包衣液流速为 5mL/min,包衣锅转速为 20r/min,包衣锅垂直倾角为30°,停止包衣后放置30℃烘箱中固化6h,即得美洲大蠊提取物微孔渗透泵片。
本发明优选的制备方法,其包括以下步骤:
按处方量将美洲大蠊提取物、氯化钠和HPMC K4M混合均匀,加95%乙醇溶液适量制软材,20目筛制粒,50℃干燥2h,过24目筛整粒,加入硬脂酸镁混匀,压片,制得片芯;将醋酸纤维素、聚乙二醇400、邻苯二甲酸二乙酯,溶于由950ml丙酮,50ml乙醇组成的混合溶液中,使其完全溶解,于包衣锅中将片芯包衣,包衣温度30℃,包衣液流速为5mL/min,包衣锅转速为20r/min,包衣锅垂直倾角为30°,停止包衣后放置30℃烘箱中固化6h,即得美洲大蠊提取物微孔渗透泵片。
附图说明
图1 美洲大蠊提取物微孔渗透泵片累计释放曲线。
具体实施方式
实施例1-8美洲大蠊提取物微孔渗透泵片的配方如表1所示:
表1 美洲大蠊提取物微孔渗透泵片的配方。
制备方法:
按处方量称取主药、渗透压促进剂、阻滞剂,混合均匀,加95%乙醇溶液适量制软材,20目筛制粒,50℃干燥2h,过24目筛整粒,加入润滑剂混匀,压片,制得片芯。将半透膜材料、增塑剂、致孔剂溶于溶剂中,即得包衣液。采用薄膜包衣,包衣温度 30℃,包衣液流速为 5mL/min,包衣锅转速为 20r/min,包衣锅垂直倾角为30°。包衣膜增重至所需质量百分比,停止包衣后放置30℃烘箱中固化6h,即得美洲大蠊提取物微孔渗透泵片。
按照中国药典2010版二部附录中的释放度测定法,采用溶出度测定法中转篮法的测定美洲大蠊提取物微孔渗透泵控释片的体外释放度,根据美洲大蠊乙醇提取物质量标准,将总氨基酸作为体外释放度的考察指标,采用茚三酮比色法在570nm波长处测定吸光度。美洲大蠊提取物在 12h 内累计释放量与时间呈零级释放模式。溶出数据见表2,累计释放曲线图见图1。
表2 美洲大蠊提取物微孔渗透泵片累计释放结果。
通过对美洲大蠊提取物微孔渗透泵片的释放度测定,结果表明,八个实施例的样品均能达到缓释效果,其中实施例1制备的样品体外释药效果明显优于其它处方,释药完全且最接近渗透泵零级释药动力学释药特点。
Claims (11)
1.一种美洲大蠊提取物微孔渗透泵片,其特征在于,先将处方量美洲大蠊提取物、渗透压促进剂、阻滞剂、润滑剂等压片制成片芯,再进行包衣制得,制备所述微孔渗透泵片的主要原辅料质量配比如下:
片芯
美洲大蠊提取物:53份;
渗透压促进剂:50-100份;
阻滞剂:50-100份;
润滑剂:0.5-2份;
包衣液
半透膜材料:30 份;
增塑剂:3-15份;
致孔剂:3-15 份;
溶剂:1-100:1。
2.根据权利要求1所述的美洲大蠊提取物微孔渗透泵片,其特征在于,所述的渗透压促进剂选自氯化钾、氯化钠、氯化镁、硫酸钾、蔗糖、乳糖、葡萄糖、甘露醇、山梨醇、果糖中的一种、二种或三种。
3.根据权利要求1所述的美洲大蠊提取物微孔渗透泵片,其特征在于,所述的阻滞剂选自羟丙甲纤维素HPMC K4M、HPMC K15M、HPMC K100M中的一种、二种或三种。
4.根据权利要求1所述的美洲大蠊提取物微孔渗透泵片,其特征在于,所述的润滑剂选自硬脂酸镁、滑石粉、微粉硅胶中的一种、二种或三种。
5.根据权利要求1所述的美洲大蠊提取物微孔渗透泵片,其特征在于,所述的半透膜材料选自醋酸纤维素和乙基纤维素中的一种或二种。
6.根据权利要求1所述的美洲大蠊提取物微孔渗透泵片,其特征在于,所述的增塑剂选自甘油、丙二醇、聚乙二醇、柠檬酸三乙酯、邻苯二甲酸二乙酯、甘油三酯中的一种、二种或三种。
7.根据权利要求1所述的美洲大蠊提取物微孔渗透泵片,其特征在于,所述的致孔剂选自甘蔗糖、甘露醇、聚乙二醇400、聚乙二醇1500、聚乙二醇2000、聚乙二醇4000、聚乙烯吡咯烷酮中的一种或二种。
8.根据权利要求1所述的美洲大蠊提取物微孔渗透泵片,其特征在于,所述的溶剂选自丙酮、乙醇、异丙醇中的一种或二种。
9.根据权利要求1所述的美洲大蠊提取物微孔渗透泵片,其特征在于,所述微孔渗透泵片每1000片原辅料组成如下:
片芯(1000片)
美洲大蠊提取物:53g;
氯化钠:80g;
HPMC K4M:80g;
硬脂酸镁:1g;
包衣液(1000mL)
醋酸纤维素:30g;
邻苯二甲酸二乙酯:6mL;
聚乙二醇400:12mL;
丙酮:乙醇:950mL:50mL。
10.一种美洲大蠊提取物微孔渗透泵片的制备方法,其特征在于,其包括以下步骤:
按处方量称取美洲大蠊提取物、渗透压促进剂、阻滞剂,混合均匀过60目筛,加95%乙醇溶液适量制软材,20目筛制粒,50℃干燥2h,过24目筛整粒,加入润滑剂混匀,压片,制得片芯;将半透膜材料、增塑剂、致孔剂溶于溶剂中,即得包衣液;采用薄膜包衣,包衣温度 30℃,包衣液流速为 5mL/min,包衣锅转速为 20r/min,包衣锅垂直倾角为30 ,停止包衣后放置30℃烘箱中固化6h,即得美洲大蠊提取物微孔渗透泵片。
11.根据权利要求10所述的一种美洲大蠊提取物微孔渗透泵片的制备方法,其特征在于,其包括以下步骤:
按处方量将美洲大蠊提取物、氯化钠和HPMC K4M混合均匀,加95%乙醇溶液适量制软材,20目筛制粒,50℃干燥2h,过24目筛整粒,加入硬脂酸镁混匀,压片,制得片芯;将醋酸纤维素、聚乙二醇400、邻苯二甲酸二乙酯,溶于由950ml丙酮,50ml乙醇组成的混合溶液中,使其完全溶解,于包衣锅中将片芯包衣,包衣温度30℃,包衣液流速为5mL/min,包衣锅转速为20r/min,包衣锅垂直倾角为30 ,停止包衣后放置30℃烘箱中固化6h,即得美洲大蠊提取物微孔渗透泵片。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410794148.7A CN104784214B (zh) | 2014-12-21 | 2014-12-21 | 一种美洲大蠊提取物微孔渗透泵片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410794148.7A CN104784214B (zh) | 2014-12-21 | 2014-12-21 | 一种美洲大蠊提取物微孔渗透泵片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104784214A true CN104784214A (zh) | 2015-07-22 |
CN104784214B CN104784214B (zh) | 2019-05-31 |
Family
ID=53549717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410794148.7A Active CN104784214B (zh) | 2014-12-21 | 2014-12-21 | 一种美洲大蠊提取物微孔渗透泵片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104784214B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1853655A (zh) * | 2005-04-28 | 2006-11-01 | 杨明 | 一种治疗溃疡性结肠炎的口服结肠靶向制剂及其制备方法 |
CN101564402A (zh) * | 2009-04-10 | 2009-10-28 | 辽东学院 | 康复新分散片及其制备方法 |
CN103239482A (zh) * | 2013-05-29 | 2013-08-14 | 四川好医生攀西药业有限责任公司 | 一种美洲大蠊胃漂浮片及其制备方法和应用 |
CN103405478A (zh) * | 2013-07-12 | 2013-11-27 | 陈光健 | 美洲大蠊提取物微凝胶及其制备方法 |
CN103919813A (zh) * | 2014-05-04 | 2014-07-16 | 昆明赛诺制药有限公司 | 一种美洲大蠊超微粉颗粒饮片的制备方法 |
-
2014
- 2014-12-21 CN CN201410794148.7A patent/CN104784214B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1853655A (zh) * | 2005-04-28 | 2006-11-01 | 杨明 | 一种治疗溃疡性结肠炎的口服结肠靶向制剂及其制备方法 |
CN101564402A (zh) * | 2009-04-10 | 2009-10-28 | 辽东学院 | 康复新分散片及其制备方法 |
CN103239482A (zh) * | 2013-05-29 | 2013-08-14 | 四川好医生攀西药业有限责任公司 | 一种美洲大蠊胃漂浮片及其制备方法和应用 |
CN103405478A (zh) * | 2013-07-12 | 2013-11-27 | 陈光健 | 美洲大蠊提取物微凝胶及其制备方法 |
CN103919813A (zh) * | 2014-05-04 | 2014-07-16 | 昆明赛诺制药有限公司 | 一种美洲大蠊超微粉颗粒饮片的制备方法 |
Non-Patent Citations (3)
Title |
---|
肖小芹等: "美洲大蠊提取物抗炎、镇痛作用的实验研究", 《中国病原生物学杂志》 * |
赵学玲等: "微孔渗透泵片的药物传递机制", 《药学学报》 * |
连潇嫣等: "吲达帕胺微孔渗透泵片的设计与制备", 《现代药物与临床》 * |
Also Published As
Publication number | Publication date |
---|---|
CN104784214B (zh) | 2019-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2720204C1 (ru) | Сублингвальная фармацевтическая композиция эдаравона и (+)-2-борнеола | |
CN107028919B (zh) | 一种复方七叶皂苷a、b脂质体水凝胶贴剂 | |
HUE027638T2 (en) | Oral film compositions containing depoxetine and tadalafil | |
US4155993A (en) | Prolonged-release pharmaceutical compositions for oral administration, their methods of making and use | |
MX2012004903A (es) | Composiciones farmaceuticas solidas que contienen un hinibidor de la integrasa. | |
JP2018184432A (ja) | ハマナツメの使用方法、ハマナツメ抽出物の使用方法及び薬物混合物の使用方法 | |
EP3193826A1 (en) | Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population | |
KR20190010578A (ko) | 새로운 다파글리플로진 결정형 및 그의 제조 방법 및 용도 | |
WO2008145064A1 (fr) | Procédé d'obtention d'un extrait contenant du séquoyitol à partir d'une espèce du genre trifolium, de soja et de ginkgo biloba, et utilisation de celui-ci | |
CN112370496A (zh) | 枸杞叶有效成分在制备预防或治疗肝纤维化药物中的应用 | |
CN1814170A (zh) | 一种治疗心血管疾病的药物滴丸及其制备方法 | |
WO2021053651A1 (en) | Extract of cocculus hirsutus for treatment of covid-19 | |
CN104784214B (zh) | 一种美洲大蠊提取物微孔渗透泵片及其制备方法 | |
CN107625954A (zh) | 含一氧化碳的血红蛋白制剂及其在抗炎症中的应用 | |
CN101677989A (zh) | 一种防治缺血性脑卒中的药物组合物及其制备方法 | |
CN104000181A (zh) | 一种用于缓解体力疲劳的组合物及其制备方法 | |
CN114533690B (zh) | 含抗凝血药物西洛他唑的新制剂及其制备方法 | |
CN113662987A (zh) | 一种用于肝癌的食蟾虫脂质体的制备方法 | |
CN107865828B (zh) | 防治结肠癌转移的口服结肠定位制剂、制备方法及其应用 | |
CN102670545A (zh) | 卡维地洛双层渗透泵型控释制剂及其制备方法 | |
EP3157516A1 (en) | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof | |
CN104434861B (zh) | 盐酸氨溴索渗透泵控释片及其制备方法 | |
CN106983838B (zh) | 一种珍珠通络丸包衣制剂及其制备方法 | |
JP2613714B2 (ja) | ヒト血小板凝集阻害剤 | |
CN103599086B (zh) | 银杏叶总黄酮双层渗透泵控释片及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: Economic and Technological Development Zone Information Industry Base in Yunnan province Kunming city forest road 650000 No. 160 Applicant after: Kunming cinorch pharmaceutical Limited by Share Ltd Address before: Economic development zone information industry base in Yunnan province Kunming city forest road 650000 Applicant before: Kunming Sinoway Natural Pharmaceuticals Co., Ltd. |
|
COR | Change of bibliographic data | ||
GR01 | Patent grant | ||
GR01 | Patent grant |